Avacta Group Plc (AVCTF)
USD 0.52
(-16.56%)
USD 0.52
(-16.56%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 51.38 Million GBP | -30.76% |
| 2022 | 74.21 Million GBP | 1184.15% |
| 2021 | 5.77 Million GBP | 4.45% |
| 2020 | 5.53 Million GBP | 112.73% |
| 2019 | 2.6 Million GBP | 27.5% |
| 2018 | 2.04 Million GBP | 22.6% |
| 2017 | 1.66 Million GBP | -1.94% |
| 2016 | 1.69 Million GBP | -25.24% |
| 2015 | 2.27 Million GBP | 2.62% |
| 2014 | 2.21 Million GBP | 5.18% |
| 2013 | 2.1 Million GBP | 37.27% |
| 2012 | 1.53 Million GBP | 70.41% |
| 2011 | 899 Thousand GBP | -28.19% |
| 2010 | 1.25 Million GBP | 65.17% |
| 2009 | 758 Thousand GBP | 175.64% |
| 2008 | 275 Thousand GBP | 27.31% |
| 2007 | 216 Thousand GBP | 1036.84% |
| 2006 | 19 Thousand GBP | -90.21% |
| 2005 | 194 Thousand GBP | -44.25% |
| 2004 | 348 Thousand GBP | -15.53% |
| 2003 | 412 Thousand GBP | -41.81% |
| 2002 | 708 Thousand GBP | 23.13% |
| 2001 | 575 Thousand GBP | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 65.01 Million GBP | 0.0% |
| 2023 Q3 | 51.38 Million GBP | -20.96% |
| 2023 FY | 51.38 Million GBP | -30.76% |
| 2023 Q4 | 51.38 Million GBP | 0.0% |
| 2023 Q1 | 65.01 Million GBP | -12.4% |
| 2022 Q4 | 74.21 Million GBP | 0.0% |
| 2022 FY | 74.21 Million GBP | 1184.15% |
| 2022 Q1 | 9.47 Million GBP | 64.01% |
| 2022 Q2 | 9.47 Million GBP | -0.01% |
| 2022 Q3 | 74.21 Million GBP | 683.06% |
| 2021 Q3 | 5.78 Million GBP | -15.96% |
| 2021 Q4 | 5.77 Million GBP | -0.02% |
| 2021 FY | 5.77 Million GBP | 4.45% |
| 2021 Q1 | 6.87 Million GBP | 24.31% |
| 2021 Q2 | 6.87 Million GBP | 0.0% |
| 2020 Q3 | 5.53 Million GBP | 49.5% |
| 2020 Q1 | 3.7 Million GBP | 0.0% |
| 2020 Q2 | 3.7 Million GBP | 0.0% |
| 2020 Q4 | 5.53 Million GBP | 0.0% |
| 2020 FY | 5.53 Million GBP | 112.73% |
| 2019 FY | 2.6 Million GBP | 27.5% |
| 2019 Q1 | 2.28 Million GBP | -39.59% |
| 2019 Q2 | 2.28 Million GBP | 0.0% |
| 2018 Q4 | 3.78 Million GBP | 0.0% |
| 2018 FY | 2.04 Million GBP | 22.6% |
| 2018 Q2 | 2.04 Million GBP | 0.0% |
| 2018 Q1 | 2.04 Million GBP | 14.41% |
| 2017 Q1 | 1.66 Million GBP | 4.13% |
| 2017 FY | 1.66 Million GBP | -1.94% |
| 2017 Q4 | 1.78 Million GBP | 0.0% |
| 2017 Q3 | 1.78 Million GBP | 7.15% |
| 2017 Q2 | 1.66 Million GBP | 0.0% |
| 2016 Q1 | 1.69 Million GBP | 0.65% |
| 2016 FY | 1.69 Million GBP | -25.24% |
| 2016 Q3 | 1.57 Million GBP | -7.31% |
| 2016 Q4 | 1.59 Million GBP | 1.59% |
| 2016 Q2 | 1.69 Million GBP | 0.0% |
| 2015 FY | 2.27 Million GBP | 2.62% |
| 2015 Q3 | 1.21 Million GBP | -46.34% |
| 2015 Q1 | 1.8 Million GBP | -1.74% |
| 2015 Q2 | 2.27 Million GBP | 25.97% |
| 2015 Q4 | 1.68 Million GBP | 38.42% |
| 2014 Q3 | 1.36 Million GBP | -38.43% |
| 2014 FY | 2.21 Million GBP | 5.18% |
| 2014 Q1 | 1.74 Million GBP | -1.47% |
| 2014 Q2 | 2.21 Million GBP | 27.13% |
| 2014 Q4 | 1.83 Million GBP | 34.65% |
| 2013 Q4 | 1.76 Million GBP | 36.69% |
| 2013 Q1 | 1.62 Million GBP | 44.93% |
| 2013 Q2 | 2.1 Million GBP | 29.1% |
| 2013 FY | 2.1 Million GBP | 37.27% |
| 2013 Q3 | 1.29 Million GBP | -38.56% |
| 2012 Q4 | 1.12 Million GBP | 0.0% |
| 2012 Q2 | 1.53 Million GBP | 0.0% |
| 2012 Q3 | 1.12 Million GBP | -26.63% |
| 2012 FY | 1.53 Million GBP | 70.41% |
| 2011 FY | 899 Thousand GBP | -28.19% |
| 2011 Q4 | 968 Thousand GBP | 0.0% |
| 2011 Q2 | 899 Thousand GBP | 0.0% |
| 2010 Q4 | 1 Million GBP | 0.0% |
| 2010 Q2 | 1.25 Million GBP | 0.0% |
| 2010 FY | 1.25 Million GBP | 65.17% |
| 2009 Q4 | 821 Thousand GBP | 0.0% |
| 2009 Q2 | 758 Thousand GBP | 0.0% |
| 2009 FY | 758 Thousand GBP | 175.64% |
| 2008 FY | 275 Thousand GBP | 27.31% |
| 2008 Q4 | 1.21 Million GBP | 0.0% |
| 2008 Q2 | 275 Thousand GBP | 0.0% |
| 2007 Q4 | 353 Thousand GBP | 0.0% |
| 2007 FY | 216 Thousand GBP | 1036.84% |
| 2006 FY | 19 Thousand GBP | -90.21% |
| 2006 Q1 | 19 Thousand GBP | 0.0% |
| 2006 Q3 | - GBP | 0.0% |
| 2005 FY | 194 Thousand GBP | -44.25% |
| 2005 Q3 | 87 Thousand GBP | 0.0% |
| 2005 Q1 | 194 Thousand GBP | 0.0% |
| 2004 FY | 348 Thousand GBP | -15.53% |
| 2004 Q1 | 348 Thousand GBP | 0.0% |
| 2004 Q3 | 350 Thousand GBP | 0.0% |
| 2003 FY | 412 Thousand GBP | -41.81% |
| 2003 Q3 | 374 Thousand GBP | 0.0% |
| 2002 FY | 708 Thousand GBP | 23.13% |
| 2001 FY | 575 Thousand GBP | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 50.26 Million USD | -2.232% |
| Skye Bioscience, Inc. | 14.07 Million USD | -265.159% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 12.926% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -6253.41% |
| Qrons Inc. | 1.48 Million USD | -3351.706% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | -223.088% |
| CSL Limited | 18.62 Billion USD | 99.724% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 29.094% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -442.853% |
| Regen BioPharma, Inc. | 5.45 Million USD | -841.547% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 31.412% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -114867.782% |
| Rebus Holdings, Inc. | 5.24 Million USD | -880.275% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -187214.548% |
| Neon Bloom, Inc. | 1.22 Million USD | -4090.626% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -25450.429% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 3.6% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -436.275% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -12089.255% |
| SQZ Biotechnologies Company | 50.03 Million USD | -2.692% |
| Intellipharmaceutics International Inc. | 12 Million USD | -327.904% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -1234.208% |
| Mesoblast Limited | 188.44 Million USD | 72.732% |
| Marizyme, Inc. | 26.67 Million USD | -92.632% |
| Genus plc | 485 Million USD | 89.405% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -779.503% |
| Pharming Group N.V. | 244.07 Million USD | 78.946% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -2456.352% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -1942.103% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -1252.263% |
| ContraFect Corporation | 32.53 Million USD | -57.96% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -2493.539% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -1242.495% |
| IMV Inc. | 37.93 Million USD | -35.466% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -336.281% |
| MultiCell Technologies, Inc. | 1617.67 USD | -3176444.042% |
| ONE Bio Corp. | 27.49 Million USD | -86.887% |
| Accustem Sciences Inc. | 1.07 Million USD | -4661.318% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 33.624% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -2329.519% |
| Q BioMed Inc. | 8.13 Million USD | -531.826% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 38.041% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -898.555% |
| Biomind Labs Inc. | 1.49 Million USD | -3328.906% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 56.717% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -468.291% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -179.22% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -3483.75% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -36063.13% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -794.32% |
| GB Sciences, Inc. | 5.41 Million USD | -848.509% |
| Alpha Cognition Inc. | 7.16 Million USD | -617.203% |
| HST Global, Inc. | 593.59 Thousand USD | -8556.773% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -3980.868% |
| Halberd Corporation | 728.71 Thousand USD | -6951.552% |
| Enzolytics Inc. | 365.26 Million USD | 85.932% |
| Agentix Corp. | 2.51 Million USD | -1946.798% |
| Resverlogix Corp. | 67.39 Million USD | 23.755% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -6026.629% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 88.451% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -2898.016% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -107.654% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -331.703% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -1302.011% |
| AVAX Technologies, Inc. | 3.99 Million USD | -1186.662% |
| Zenith Capital Corp. | 27.56 Thousand USD | -186290.511% |
| Genscript Biotech Corporation | 1.32 Billion USD | 96.124% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -21431.59% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -1276.052% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -7447.508% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -1795.015% |
| Kadimastem Ltd | 3.5 Million USD | -1366.133% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -76676.883% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -10957.911% |
| LadRx Corporation | 2.2 Million USD | -2235.167% |
| Cell Source, Inc. | 15.8 Million USD | -225.09% |
| Regen BioPharma, Inc. | 5.45 Million USD | -841.547% |
| NovAccess Global Inc. | 7.86 Million USD | -553.705% |
| Affymax, Inc. | 8.87 Million USD | -479.258% |
| Itoco Inc. | 1.65 Million USD | -3008.367% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -2404.722% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -749.496% |
| Mobile Lads Corp. | 1.31 Million USD | -3812.152% |
| CytoDyn Inc. | 127.89 Million USD | 59.821% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -122835.955% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -3180.564% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -365.23% |
| SYBLEU INC | 681.41 Thousand USD | -7441.095% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -742.13% |
| International Stem Cell Corporation | 5.27 Million USD | -873.773% |
| Bioxytran, Inc. | 3.24 Million USD | -1481.351% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -8111.132% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -1012.944% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -25.344% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -130.793% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -2437.095% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -838.043% |
| Neutra Corp. | 973.52 Thousand USD | -5178.322% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -77.101% |
| PureTech Health plc | 125.58 Million USD | 59.082% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -1267.695% |
| IXICO plc | 1.9 Million USD | -2604.111% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -150.309% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 50.267% |
| CSL Limited | 18.62 Billion USD | 99.724% |
| Cellectis S.A. | 249.36 Million USD | 79.394% |